Supernus Pharmaceuticals, Inc. (SUPN): Cost of Revenue
$74.56M
Year ended 2025-12-31
$99.03M
Trailing 12 months to 2026-06-30
-5.1%
3-year compound annual growth
+7.3%
5-year compound annual growth
+24.4%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $74.56M | -4.3% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $77.91M | -7.0% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $83.78M | -3.9% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $87.22M | n/a | 2025-02-25, From 2022-01-01 |
| No annual figure between 2020-12-31 and 2022-12-31. | |||
| 2020-12-31 | $52.46M | +214.9% | 2021-03-08, From 2020-01-01 |
| 2019-12-31 | $16.66M | +8.5% | 2021-03-08, From 2019-01-01 |
| 2018-12-31 | $15.36M | +0.9% | 2021-03-08, From 2018-01-01 |
| 2017-12-31 | $15.21M | +26.9% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $11.99M | +42.3% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $8.42M | +46.3% | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | $5.76M | +421.6% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $1.10M | n/a | 2017-01-20, From 2013-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $74.56M | -4.3% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $363.83M | +1.6% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $149.75M | -12.1% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $326.20M | -52.1% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $12.98M | +19.3% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $77.67M | +27.5% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $317.31M | +24.9% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $100.71M | +161.7% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $400.94M | -18.9% |
Compare SUPN, AMPH, PCRX, EBS side by side · Screen every company in Pharmaceutical Preparations ↗